The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
Despite this effort, state officials and health plans reported that beneficiaries, many of whom have low literacy skills or who are non-English speaking, continue to be confused and alarmed by receipt of the Integrated Denial Notice, because it may still appear that a service had been denied when it is covered under Medicaid
Are results from P-Long permanent
Are there any specialized dosing considerations for patients with chronic conditions like pernicious anemia
Before & Preparation There is no need for preparation for this procedure
Megan B